Sign inCreate account

Report workspace tools

NCT02213744TERMINATEDanonymous

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

Sponsor

Source record

Merrimack Pharmaceuticals

Phase

Source record

Phase 2/3

Modality

AI-normalized

small molecule

Target

AI-normalized

HER2-Positive Breast Cancer

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab

Source & freshness

Source record

NCT ID

NCT02213744

Original source

ClinicalTrials.gov

Source last updated

Jan 06, 2017

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02213744

Title

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

Sponsor

Merrimack Pharmaceuticals

Status

TERMINATED

Phase

Phase 2/3

Condition raw

Breast Cancer, HER2 Positive Breast Cancer

Condition normalized

Breast Cancer, HER2 Positive Breast Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab

Target normalized

HER2-Positive Breast Cancer

Interventions

MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab

Public preview

Source record

The clinical trial aimed to evaluate the efficacy of MM-302 combined with trastuzumab compared to physician's choice chemotherapy plus trastuzumab in patients with HER2-positive locally advanced or metastatic breast cancer. The study was terminated due to a lack of demonstrated benefit over the control group as determined by the Data Monitoring Committee (DMC).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02213744

Status

TERMINATED

Phase

Phase 2/3

Sponsor

Merrimack Pharmaceuticals

Executive brief

Investment-Ready Snapshot

The clinical trial aimed to evaluate the efficacy of MM-302 combined with trastuzumab compared to physician's choice chemotherapy plus trastuzumab in patients with HER2-positive locally advanced or metastatic breast cancer. The study was terminated due to a lack of demonstrated benefit over the control group as determined by the Data Monitoring Committee (DMC).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 06, 2017
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02213744

Indication

Breast Cancer

Modality

small molecule

Target

HER2-Positive Breast Cancer

Intervention

MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.